Showing posts with label Outbreak. Show all posts
Showing posts with label Outbreak. Show all posts

Sunday, October 21, 2012

Latest Meningitis Outbreak Toll: 20 Deaths and 257 Infections, CDC Says

By Steven Reinberg and Margaret Steele
HealthDay Reporters

THURSDAY, Oct. 18 (HealthDay News) -- Another person has died and 10 more have been sickened in the nationwide meningitis outbreak believed to be tied to contaminated steroid injections, bringing the totals to 20 deaths and 257 infections, U.S. health officials reported Thursday.

It's suspected that the steroid, contaminated with a fungus, was manufactured by the New England Compounding Center of Framingham, Mass. Last month the company voluntarily recalled three lots of the steroid, methylprednisolone acetate, which is injected into patients for back and joint pain. The company has since shut down operations and stopped distributing its products, health officials said.

On Thursday, federal health officials said they'd confirmed the presence of a fungus known as Exserohilum rostratum in unopened vials of the steroid from one of the three lots. The laboratory confirmation further links the steroid from these lots and the subsequent infections to the Massachusetts specialty pharmacy, said officials from the U.S. Centers for Disease Control and Prevention and the U.S. Food and Drug Administration.

Tests on the other two lots and other injectable products from the company are continuing, officials said.

The CDC and state health departments estimate that roughly 14,000 patients may have gotten steroid injections from the three lots, and nearly 97 percent of them have been contacted for medical follow-up.

Meningitis is potentially fatal inflammation of the lining surrounding the brain and spinal cord.

All of the 254 fungal meningitis patients were thought to be injected with methylprednisolone acetate, according to the CDC.

There have been three cases of what the CDC calls "peripheral joint infection," meaning an infection in a knee, hip, shoulder or elbow. These joint infections aren't considered as dangerous as injections near the spine for back pain that have been linked to the potentially fatal meningitis infections.

The 14,000 people who may have gotten injections of the steroid include not only patients who got shots for back pain and are most at risk for meningitis, but also others who received shots for pain in their knees and shoulders.

All of the infected patients are thought to have received the medication from the Massachusetts pharmacy, according to the CDC.

The FDA said it was advising all health-care professionals to follow up with any patients who were given any injectable drug from or produced by the New England Compounding Center. These drugs include medications used in eye surgery, and a heart solution purchased from or produced by the company after May 21.

The New England Compounding Center is what's known as a compounding pharmacy. These pharmacies combine, mix or alter ingredients to create specific drugs to meet the specific needs of individual patients, according to the FDA. Such customized drugs are frequently required to fill special needs, such as a smaller dose, or the removal of an ingredient that might trigger an allergy in a patient.

The CDC on Thursday had the following state-by-state breakdown of cases: Florida: 13 cases, including 3 deaths; Idaho, 1 case; Illinois, 1 case; Indiana: 34 cases, including 2 deaths; Maryland: 16 cases, including 1 death; Michigan: 49 cases, including 4 deaths; Minnesota: 7 cases; New Hampshire: 8 cases; New Jersey: 13 cases; New York: 1 case; North Carolina: 2 cases; Ohio: 10 cases; Pennsylvania: 1 case; Tennessee: 63 cases, including 8 deaths; Texas: 1 case; Virginia: 37 cases, including 2 deaths.

Health officials said they expect to see more cases of the rare type of meningitis, which is not contagious, because symptoms can take a month or more to appear.

Infected patients have developed a range of symptoms approximately one to four weeks following their injection. People who have had a steroid injection since July, and have any of the following symptoms, should talk to their doctor as soon as possible: worsening headache, fever, sensitivity to light, stiff neck, new weakness or numbness in any part of your body, slurred speech, the CDC said.

Infected patients must receive intravenous drugs in a hospital.

Compounding pharmacies like the New England Compounding Center traditionally started out as community-based neighborhood druggists. But over time, the practices of some compounding pharmacies have expanded, sometimes beyond their intended limits, experts explained.

According to the Associated Press, this isn't the first time the New England Compounding Center has encountered problems with contaminated injections. In 2007, the company settled a lawsuit that claimed that an 83-year-old man died in 2004 after contracting fatal bacterial meningitis from a shot produced by the compounding center. The pharmacy reached a settlement with the man's widow before the case went to trial, the AP said.

Compounding pharmacies aren't subject to the same FDA oversight as regular drug manufacturers are, and some members of Congress now say the meningitis outbreak highlights the need for more regulatory control.

The CDC released a list of the approximately 75 health-care facilities that received contaminated product.

MedicalNewsCopyright © 2012 HealthDay. All rights reserved. SOURCES: Oct. 18, 2012, news release, U.S. Centers for Disease Control and Prevention, and U.S. Food and Drug Administration; Oct. 18, 2012, updated statistics, U.S. Centers for Disease Control and Prevention; Associated Press



View the original article here

Saturday, October 20, 2012

Official: Pharmacy Tied to Meningitis Outbreak May Have Broken State Law

By Steven Reinberg
HealthDay Reporter

THURSDAY, Oct. 11 (HealthDay News) -- The company at the center of the ongoing meningitis outbreak appears to have violated Massachusetts law by producing and distributing large quantities of a contaminated steroid compound, a state health official said Thursday.

According to Massachusetts law, so-called compounding pharmacies like the company in question -- the New England Compounding Center -- are only licensed to produce medications to fill single prescriptions for individual patients, said Dr. Madeleine Biondolillo, director of the Department of Public Health's Bureau of Health Care Safety and Quality.

"Through the investigation, it looks like they have violated that aspect of the state licensing regulations despite their assertion that they were operating under the regulation," Biondolillo said during an afternoon news conference.

"Yesterday, the Massachusetts board of pharmacies issued an alert to all compounding pharmacies to reinforce with them the rules they must abide by in Massachusetts," she added. "Compounding can only be conducted upon the receipt of a patient-specific prescription."

Biondolillo said more oversight of compounding pharmacies is needed, both on the state and federal levels.

Compounding pharmacies -- which historically started out as community-based neighborhood druggists -- combine, mix or alter ingredients to create specific drugs to meet the specific needs of individual patients, according to the U.S. Food and Drug Administration. Such customized drugs are frequently required to fill special needs, such as a smaller dose, or the removal of an ingredient that might trigger an allergy in a patient.

But over time, the practices of some compounding pharmacies have expanded, often beyond their intended limits, experts explained.

As of Thursday, 170 people had confirmed meningitis infections due to the contaminated steroids and 14 had died. These illnesses and deaths occurred in 11 of the 23 states where the steroids were shipped, Dr. J. Todd Weber, chief of U.S. Centers for Disease Control and Prevention's Prevention and Response Branch, Division of Healthcare Quality Promotion, said during the news conference.

Meningitis is a potentially fatal inflammation of the lining of the brain and spinal cord.

The CDC said infections and deaths had been reported in the following states: Florida: 7 cases, including 2 deaths; Idaho, 1 case; Indiana: 21 cases, including 1 death; Maryland: 13 cases, including 1 death; Michigan: 39 cases, including 3 deaths; Minnesota: 3 cases; New Jersey: 2 cases; North Carolina: 2 cases; Ohio: 3 cases; Tennessee: 49 cases, including 6 deaths; Virginia: 30 cases, including 1 death.

Fungus linked to the outbreak has been found in 50 vials of the drug taken from the manufacturer and from pain clinics around the country, Deborah Autor, the FDA's deputy commissioner for global regulatory operations and policy, said at the news conference.

The company is believed to have shipped more than 17,000 vials of the steroid drug, called methylprednisolone acetate, to 23 states.

"The first cases from Tennessee had an infection from a fungus known as aspergillus, the CDC's Weber said. "Since that time, confirmed cases have all had infection caused by a different fungus known as exserohilum."

Exserohilumm infection has been confirmed in 10 people with meningitis, and aspergillus has been confirmed in only one person -- the first case, Weber said. Both types of infection are extremely rare, he said, adding, "This is new territory for public health and the clinical community."

As many as 14,000 people may have been exposed to the contaminated steroids, Weber said. The CDC has so far been able to contact some 11,000 of those patients, he said.

The most serious infections have been reported by those receiving injections in the lower back, near the spine, to relieve chronic back pain. Others have gotten shots for pain in joints like the knee, ankle or shoulder, Weber said.

Weber also reported the first case of infection in someone who received an injection in a joint. "This person received an injection from one of the three recalled lots [recalled by the New England Compounding Center]," he said. Whether the infection is meningitis hasn't been confirmed yet, he said.

The New England Compounding Center was shut down on Oct. 3, Autor said. Massachusetts officials have also pulled the company's license to operate.

Autor said the FDA also inspected another Massachusetts-based compounding pharmacy, Ameridose, which is affiliated with the New England Compounding Center. That inspection failed to turn up any irregularities and no recall of its products has occurred so far, she said.

MedicalNewsCopyright © 2012 HealthDay. All rights reserved. SOURCES: Oct 11, 2012, press conference with J. Todd Weber, M.D, incident manager, Multistate Meningitis Outbreak, and chief, Prevention and Response Branch, Division of Healthcare Quality Promotion, U.S. Centers for Disease Control and Prevention; Madeleine Biondolillo, M.D., director, Department of Public Health, Bureau of Health Care Safety and Quality, Massachusetts Department of Public Health; Deborah Autor, J.D., deputy commissioner, Global Regulatory Operations and Policy, U.S. Food and Drug Administration



View the original article here

Twitter Delicious Facebook Digg Stumbleupon Favorites More

 
Design by Free WordPress Themes | Bloggerized by Lasantha - Premium Blogger Themes | Facebook Themes